



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: lanthanum

Brand Name: Fosrenol

Medication Class: Phosphate removing agent

FDA Approved Uses: to reduce serum phosphate in patients with end-stage renal disease.

Usual Dose: Initial dose of 750mg -1500 mg a day. Most patients require between 1500mg – 3000mg a day to maintain phosphate levels less than 6.0 mg/dl. The total daily dose should be divided and taken with meals.
Note: in studies, doses up to 3750mg were evaluated.

Duration of Therapy: Indefinite

Criteria for Use: *(bullet points below are all inclusive unless otherwise note)*

- Clinically diagnosed hyperphosphatemia due to renal failure.
- Failed / intolerant to calcium based binding agent (Tums, Os-Cal, Caltrate, Phoslo)
- Or
- Failed/ intolerant to Rocaltrol
- Or
- Failed intolerant to aluminum based binding agents (AlternGel, Alu-tabs, Amphojel) and
- Failed/ intolerant to Renagel

Cautions:

The following conditions were not included in Fosrenol clinical studies.

- Acute peptic ulcer disease
- Ulcerative colitis
- Crohn's disease
- Bowel obstruction

Contraindications:

- None known

Not Approved if:

- The above criteria is not met.

P&T Approval: _____ Date: _____